Twist Bioscience reports record Q3 revenue $96.1M (+18% YoY); swings to GAAP net income $20.4M

Twist Bioscience Corp

2025-Q3 EPS reported -$0.85 revenue$277,563,000

Record revenue $96.1M, up 18% YoY; NGS revenue grew 27% to $55.3M.
Gross margin improved to 53.4% from 43.3% YoY; net income $20.4M ($0.34/share) vs loss $85.6M.
FY2025 revenue guidance raised to $374-376M; gross margin guidance raised to 50.5%-51%.
Adjusted EBITDA loss narrowed to $(8.0)M from $(22.0)M; expect breakeven by end of FY2026.
Added ~184 net new customers; shipped 237,000 genes, up 12% YoY.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.